Get the Stockscreener App
1.01
0.50%
0.005
After Hours:
1.02
0.01
+0.99%
Adial Pharmaceuticals Inc stock is traded at $1.01, with a volume of 29,149.
It is up +0.50% in the last 24 hours and up +4.01% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
See More
Previous Close:
$1.005
Open:
$1.01
24h Volume:
29,149
Relative Volume:
0.24
Market Cap:
$6.41M
Revenue:
-
Net Income/Loss:
$-6.07M
P/E Ratio:
-0.134
EPS:
-7.54
Net Cash Flow:
$-7.34M
1W Performance:
-0.98%
1M Performance:
+4.01%
6M Performance:
-40.59%
1Y Performance:
-56.47%
1-Day Range:
$0.9922
$1.02
1-Week Range:
$0.9753
$1.02
52-Week Range:
$0.765
$4.1699
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - citybiz
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference - The Manila Times
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate - AOL
Adial Pharmaceuticals patent expands for alcohol disorder drug - Investing.com
Adial Pharmaceuticals patent expands for alcohol disorder drug By Investing.com - Investing.com Canada
Adial Pharmaceuticals Receives Notice of Allowance for U.S. - GlobeNewswire
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery - GlobeNewswire
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 46.2% in September - Defense World
Analyzing ADI’s price-to-book ratio for the last quarter - US Post News
Adial Pharmaceuticals completes key study stage for AUD drug - Investing.com
Adial Pharmaceuticals Announces Database Lock in - GlobeNewswire
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - StockTitan
Analog Devices Inc. (ADI) Stock: A Year of Declines and Increases - The InvestChronicle
MQS Management LLC Increases Stock Position in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Addex Therapeutics Reports Profitable H1 2024 - TipRanks
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit - GlobeNewswire
Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily
ADMA Biologics stock soars to all-time high of $19.36 - Investing.com
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest? - Yahoo Finance
Adial Pharmaceuticals (NASDAQ:ADIL) versus Galapagos (NASDAQ:GLPG) Head-To-Head Comparison - Defense World
Analog Devices (NASDAQ:ADI) shareholders notch a 17% CAGR over 5 years, yet earnings have been shrinking - Yahoo Finance
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Eagle-Tribune
ADM Investor Services Singapore Becomes Abaxx Exchange's Third Clearing and Trading Member - GlobeNewswire
Raymond James lifts Adma Biologics Inc [ADMA] price estimate. Who else is bullish? - The DBT News
Keeping an Eye on Adma Biologics Inc (ADMA) After Insider Trading Activity - Knox Daily
Adma Biologics Inc (NASDAQ:ADMA) stock crossing the finish line today - US Post News
Analytical Overview: Adma Biologics Inc (ADMA)’s Ratios Tell a Financial Story - The Dwinnex
A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News
ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion - Marketscreener.com
ADMA Biologics set to join S&P SmallCap 600 index By Investing.com - Investing.com Canada
Take off with Applied Dna Sciences Inc (APDN): Get ready for trading - SETE News
ADMA Biologics Set to Join S&P SmallCap 600 Index - Yahoo Finance
Adma Biologics Inc (ADMA) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Adma Biologics Inc (ADMA) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News
Balance Sheet Insights: Applied Dna Sciences Inc (APDN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
The Attractiveness of Investing In Analog Devices Inc. (ADI) is Growing - Knox Daily
Applied Dna Sciences Inc (APDN) is a good investment, but the stock may be undervalued - US Post News
Applied Dna Sciences Inc: Navigating Market Fluctuations with a 14.11M Market Cap - The InvestChronicle
Small-cap stars are buying this forecast-smashing biotech - Citywire New Model Adviser
Q2 2026 EPS Estimates for Analog Devices, Inc. Decreased by Analyst (NASDAQ:ADI) - MarketBeat
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Declines By 14.5% - Defense World
Analog Devices (NASDAQ:ADI) shareholders notch a 16% CAGR over 5 years, yet earnings have been shrinking - Simply Wall St
ADMA Shares Experience Surge in Value - Knox Daily
Analog Devices Inc. (ADI) did well last session? - US Post News
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Increases By 8.3% - Defense World
Reviewing Adial Pharmaceuticals (NASDAQ:ADIL) and Ultragenyx Pharmaceutical (NASDAQ:RARE) - Defense World
EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder - MSN
Brookline Capital Management Research Analysts Cut Earnings Estimates for Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Thinking about buying stock in Rivian Automotive, Joby Aviation, - GuruFocus.com
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):